Effect of the Administration of L-Carnitine on Body Weight in Women in Crossfit Training
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03436277 |
Recruitment Status : Unknown
Verified February 2018 by Diana Mercedes Hernández Corona, University of Guadalajara.
Recruitment status was: Not yet recruiting
First Posted : February 19, 2018
Last Update Posted : February 20, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Body Weight Changes | Drug: L-Carnitine Dietary Supplement: Sucralose | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effect of the Administration of L-Carnitine on Body Fat Percentage and Body Weight in Overweight Women in Crossfit Training. |
Estimated Study Start Date : | December 17, 2018 |
Estimated Primary Completion Date : | February 2019 |
Estimated Study Completion Date : | May 2019 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Sucralose 1,5 g
|
Dietary Supplement: Sucralose
Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
Other Name: Trichlorogalacto-sucrose |
Experimental: L-Carnitine
L- Carnitine 1,5 g
|
Drug: L-Carnitine
L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
Other Names:
|
- Body Fat [ Time Frame: 8 weeks ]Calulated by Durnin formula. Results are reported in percentage and kg
- Lean body mass [ Time Frame: 8 weeks ]Calulated by Durnin formula. Results are reported in percentage and kg
- Body Weight [ Time Frame: 8 weeks ]Subject go up onto the scale and stand still over the center of the scale with body weight evenly distributed between both feet. Omron hbf-514c an digital scale and results are reported in kg with a decimal.
- Arm muscle circumference [ Time Frame: 8 weeks ]The right arm measure to the nearest centimeter with a measuring tape. Then, triceps skinfold thickness, an established measure of fat stores, measure to the nearest millimeter in the right arm using a skinfold caliper
- Waist circumference [ Time Frame: 8 weeks ]
Flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters.
Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters.
Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters.
- Body Mass Index [ Time Frame: 8 weeks ]Body mass divided by the square of the body height, and reported in units of kg/m2.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Volunteers who practice crossfit regularly (who have 3 months prior to the beginning of the study practicing crossfit).
- Volunteers with a body mass index equal to or greater than 25 Kg/m2.
- Volunteers who do not have allergies to L-Carnitine or any of its components.
- Informed consent signed
- Women with a recommendation of nutrition two weeks prior to the start of the study.
- Body weight stable the last 3 months.
Exclusion Criteria:
- Volunteers with pathologies such as diabetes, hypertension, metabolic syndrome and allergies.
- Women with confirmed or suspected pregnancy.
- Women under lactation and/or puerperium.
- Hypersensibilility to L-Carnitine or Sucralose.
- Kown of renal, hepatic or thyroid deseased.
- Current or previous treatment diet (3 months before inclusion to the study).
- Current pharmacological treatment for loose body weight or 3 months before inclusion to the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03436277
Contact: Diana M Hernández, PhD | +521 3314856584 | diana.hcorona@academicos.udg.mx | |
Contact: Tonatiuh González, PhD | +521 3314664863 | drtonatiuhgh@live.com.mx |
Mexico | |
Centro Universitario de Tonalá | |
Tonalá, Jalisco, Mexico, 45425 |
Principal Investigator: | Diana M Hernández | University of Guadalajara |
Responsible Party: | Diana Mercedes Hernández Corona, PhD of Pharmacology, University of Guadalajara |
ClinicalTrials.gov Identifier: | NCT03436277 |
Other Study ID Numbers: |
LC-CUT-DMHC |
First Posted: | February 19, 2018 Key Record Dates |
Last Update Posted: | February 20, 2018 |
Last Verified: | February 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Overweight Obesity L-Carnitine Body weight Body fat percentage |
Body Weight Body Weight Changes |